BioInvest BREAKING News – SANGAMO – Q2 CALL BONANZA – Reiterate BUY (And Short CRSP, EDIT, NTLA) First Hemophilia A SB-525 Results Ideal In The ALTA Study-MPSII Patient 6 Treated with SB-913 in the CHAMPIONS Study
-First patient treated in the SB-318 Phase 1/2 EMPOWERS Study for MPS Enrolled the first patient in the Phase 1/2 Thales Study of ST-400 gene-edited cell therapy for beta-thalassemia
Presented further ZFN Safety via the Most Sensitive Assays ..
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.